Journal of the American College of Cardiology
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.
Michael E Nassif, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Maria Luisa Peña-Peña, Roberto Barriales-Villa, Ozlem Bilen, Melissa Burroughs, Brian L Claggett, Juan Pablo Costabel, Edileide de Barros Correia, Anne M Dybro, Perry Elliott, Neal K Lakdawala, Gregory D Lewis
Published: 202510.1016/j.jacc.2025.10.059
Abstract
BACKGROUND: The cardiac myosin inhibitor aficamten was significantly more effective than metoprolol at improving exercise tolerance in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a head-to-head,…
Preview only. Read the full abstract at the source